Share Price and Basic Stock Data
Last Updated: December 10, 2025, 10:47 pm
| PEG Ratio | -4.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Amerise Biosciences Ltd, operating in the pharmaceuticals sector, has faced significant challenges in revenue generation over the past several years. The company’s reported sales have been notably low, with a mere ₹0.01 Cr for FY 2023 and a slight uptick to ₹0.04 Cr in FY 2024, followed by a projected increase to ₹0.19 Cr in FY 2025. This trend indicates a gradual recovery, albeit from a very low base. Historically, the company has struggled to maintain consistent sales, recording zero revenues in many quarters since June 2022. The pharmaceutical industry often demands substantial investments in research and development, and Amerise’s inability to generate steady revenues raises concerns about its operational viability and market positioning. Furthermore, the lack of any significant sales momentum raises questions about its product pipeline and market strategy.
Profitability and Efficiency Metrics
The profitability metrics for Amerise Biosciences paint a picture of ongoing struggles, with an operating profit margin (OPM) that swung dramatically, recording a positive 50% in March 2024 but then declining to -16.67% in June 2025. This volatility underscores the challenges in managing expenses relative to revenues, particularly given the operating losses reported in several fiscal years. The company had a net profit of ₹0.05 Cr in FY 2025, a stark contrast to the losses seen in previous years, indicating a potential turning point. However, with a high P/E ratio of 101, investor expectations may be misaligned with the company’s current performance. The return on equity (ROE) and return on capital employed (ROCE) both stood at a modest 0.19%, suggesting that while there may be some operational improvements, overall returns remain low, reflecting inefficiencies that need addressing.
Balance Sheet Strength and Financial Ratios
When examining the balance sheet of Amerise Biosciences, it becomes evident that the company is navigating a challenging financial landscape. Total assets stood at ₹8.46 Cr as of March 2025, with no borrowings reported, highlighting a debt-free status that could be seen as a strength. However, the reserves have been negative, recorded at -₹1.28 Cr, which raises concerns about the company’s retained earnings and ability to reinvest in its operations. The current ratio of 0.01 suggests a precarious liquidity position, indicating potential difficulties in meeting short-term obligations. Additionally, the interest coverage ratio is remarkably high at 39.00x, primarily due to the absence of debt, but this figure may mislead investors regarding true operational performance given the minimal revenue generated. Overall, while the lack of debt is a positive aspect, the financial health signals a need for strategic restructuring to improve profitability and liquidity.
Shareholding Pattern and Investor Confidence
Amerise Biosciences has a completely public shareholding pattern, with public ownership reported at 100% as of March 2025. This structure could indicate a broad base of retail investors, which may provide stability but also reflects a lack of institutional backing. The number of shareholders has increased significantly, rising from 18,842 in December 2022 to 36,595 by March 2025. This growth suggests a growing interest among retail investors, possibly driven by the company’s recent improvements in net profit and operational metrics. However, the absence of institutional investors raises questions about the credibility and market perception of the company. Investors might view this as a double-edged sword; while increased public interest is positive, the lack of institutional support could indicate skepticism about the company’s long-term viability and growth potential.
Outlook, Risks, and Final Insight
Looking ahead, Amerise Biosciences faces both opportunities and significant risks. On one hand, the recent uptick in revenue and net profit suggests a potential turnaround, which could attract further investor interest. However, the company must address its ongoing challenges, particularly in generating consistent sales and improving profitability metrics. The negative reserves and low liquidity ratios pose considerable risks, potentially limiting the company’s ability to invest in growth or weather adverse market conditions. Additionally, the high P/E ratio may lead to volatility if the company fails to meet market expectations in the coming fiscal periods. Investors should remain cautious, weighing the signs of recovery against the backdrop of a historically underperforming business model and the uncertainties that lie ahead. A prudent approach would be to monitor the company’s strategic initiatives and operational developments closely, as these will be critical in determining whether the recent positive trends can be sustained.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Amerise Biosciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,260 Cr. | 390 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,465.89 Cr | 1,157.79 | 52.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.19 | 0.06 |
| Expenses | 0.04 | 0.02 | 0.05 | 0.02 | 0.07 | 0.04 | 0.06 | 0.02 | 0.05 | 0.03 | 0.02 | 0.08 | 0.07 |
| Operating Profit | -0.04 | -0.02 | -0.05 | -0.02 | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 |
| OPM % | 50.00% | 57.89% | -16.67% | ||||||||||
| Other Income | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.04 | -0.01 | -0.05 | -0.02 | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.04 | -0.01 | -0.05 | -0.02 | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 |
| EPS in Rs | -0.01 | -0.00 | -0.01 | -0.00 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.00 | -0.00 | 0.02 | -0.00 |
Last Updated: August 1, 2025, 7:55 am
Below is a detailed analysis of the quarterly data for Amerise Biosciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.19 Cr. (Mar 2025) to 0.06 Cr., marking a decrease of 0.13 Cr..
- For Expenses, as of Jun 2025, the value is 0.07 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.08 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.01 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to -0.01 Cr., marking a decrease of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is -16.67%. The value appears to be declining and may need further review. It has decreased from 57.89% (Mar 2025) to -16.67%, marking a decrease of 74.56%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to -0.01 Cr., marking a decrease of 0.12 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to -0.01 Cr., marking a decrease of 0.12 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.00. The value appears to be declining and may need further review. It has decreased from 0.02 (Mar 2025) to 0.00, marking a decrease of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 1.18 | -0.00 | -0.00 | 9.58 | 0.01 | 0.04 | 0.19 | 0.25 |
| Expenses | 0.03 | 0.05 | 0.03 | 0.94 | 0.02 | 1.18 | 0.15 | 0.17 | 9.03 | 0.13 | 0.19 | 0.18 | 0.20 |
| Operating Profit | -0.03 | -0.05 | -0.03 | -0.94 | -0.02 | -0.00 | -0.15 | -0.17 | 0.55 | -0.12 | -0.15 | 0.01 | 0.05 |
| OPM % | -0.00% | 5.74% | -1,200.00% | -375.00% | 5.26% | 20.00% | |||||||
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.17 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Profit before tax | -0.03 | -0.05 | -0.03 | -0.94 | -0.02 | -0.00 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.05 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | ||
| Net Profit | -0.03 | -0.05 | -0.03 | -0.94 | -0.02 | -0.00 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.05 |
| EPS in Rs | -0.00 | -0.01 | -0.00 | -0.14 | -0.00 | -0.00 | -0.02 | -0.05 | 0.08 | -0.02 | -0.02 | 0.00 | 0.02 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -66.67% | 40.00% | -3033.33% | 97.87% | 100.00% | -126.67% | 261.76% | -121.82% | -25.00% | 106.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.67% | -3073.33% | 3131.21% | 2.13% | -226.67% | 388.43% | -383.58% | 96.82% | 131.67% |
Amerise Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -73% |
| TTM: | 525% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 16% |
| 3 Years: | -74% |
| TTM: | 138% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -3% |
| 3 Years: | -10% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 0% |
| 3 Years: | -2% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| Reserves | 0.00 | -0.05 | -0.07 | -1.01 | -1.03 | -1.03 | -1.18 | -1.52 | -0.97 | -1.09 | -1.23 | -1.23 | -1.28 |
| Borrowings | 0.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | 0.02 | 0.60 | 0.54 | 6.27 | 0.04 | 0.01 | 3.08 | 3.06 |
| Total Liabilities | 7.20 | 6.56 | 6.54 | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 8.39 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 5.14 | 4.82 | 5.89 | 2.34 | 2.31 | 0.54 | 5.37 | 3.04 | 4.69 | 4.57 | 2.27 | 2.38 | 3.77 |
| Other Assets | 2.06 | 1.74 | 0.65 | 3.30 | 3.28 | 5.06 | 0.66 | 2.59 | 7.30 | 1.08 | 3.12 | 6.08 | 4.62 |
| Total Assets | 7.20 | 6.56 | 6.54 | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 8.39 |
Below is a detailed analysis of the balance sheet data for Amerise Biosciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.61 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.61 Cr..
- For Reserves, as of Sep 2025, the value is -1.28 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -1.23 Cr. (Mar 2025) to -1.28 Cr., marking a decline of 0.05 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3.06 Cr.. The value appears to be improving (decreasing). It has decreased from 3.08 Cr. (Mar 2025) to 3.06 Cr., marking a decrease of 0.02 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.39 Cr.. The value appears to be improving (decreasing). It has decreased from 8.46 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.07 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 3.77 Cr.. The value appears strong and on an upward trend. It has increased from 2.38 Cr. (Mar 2025) to 3.77 Cr., marking an increase of 1.39 Cr..
- For Other Assets, as of Sep 2025, the value is 4.62 Cr.. The value appears to be declining and may need further review. It has decreased from 6.08 Cr. (Mar 2025) to 4.62 Cr., marking a decrease of 1.46 Cr..
- For Total Assets, as of Sep 2025, the value is 8.39 Cr.. The value appears to be declining and may need further review. It has decreased from 8.46 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.07 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-1.28 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.62 | -0.05 | -0.03 | -0.94 | -0.02 | 0.00 | -0.15 | -0.17 | 0.47 | -0.21 | -0.15 | 0.01 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,382.67 | 236.98 | 0.00 | 0.00 | 0.00 | |||||||
| Inventory Days | 0.00 | 0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 1,382.67 | 236.98 | 0.00 | 0.00 | 0.00 | |||||||
| Working Capital Days | 1,376.48 | -1.91 | -1,460.00 | -182.50 | -5,897.63 | |||||||
| ROCE % | -0.36% | -0.73% | -0.46% | -15.49% | -0.36% | 0.00% | -2.72% | -6.46% | 10.18% | -2.12% | -2.73% | 0.19% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | -0.02 | -0.02 | 0.08 | -0.05 |
| Diluted EPS (Rs.) | 0.00 | -0.02 | -0.02 | 0.08 | -0.05 |
| Cash EPS (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.81 | 0.81 | 0.83 | 0.85 | 0.77 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.81 | 0.81 | 0.83 | 0.85 | 0.77 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 1.36 | 0.00 |
| PBDIT / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| PBIT / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| PBT / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| Net Profit / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| Return on Networth / Equity (%) | 0.10 | -2.71 | -2.15 | 9.73 | -6.62 |
| Return on Capital Employeed (%) | 0.14 | -2.71 | -2.11 | 9.59 | -6.62 |
| Return On Assets (%) | 0.06 | -2.71 | -2.10 | 4.58 | -5.99 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 1.02 | 0.00 |
| Current Ratio (X) | 0.01 | 1.48 | 0.36 | 0.99 | 0.03 |
| Quick Ratio (X) | 0.01 | 1.48 | 0.36 | 0.99 | 0.03 |
| Interest Coverage Ratio (X) | 39.00 | -486.00 | -1188.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 29.50 | -486.00 | -1188.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 5.99 | 4.34 | 4.70 | 9.06 | 10.88 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 |
| EV / EBITDA (X) | 767.96 | -29.76 | -39.57 | 16.49 | -32.28 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| Price / BV (X) | 1.12 | 0.81 | 0.83 | 1.59 | 2.14 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| EarningsYield | 0.00 | -0.03 | -0.02 | 0.06 | -0.03 |
After reviewing the key financial ratios for Amerise Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.81. There is no change compared to the previous period (Mar 24) which recorded 0.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.81. There is no change compared to the previous period (Mar 24) which recorded 0.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 15. It has increased from -2.71 (Mar 24) to 0.10, marking an increase of 2.81.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 10. It has increased from -2.71 (Mar 24) to 0.14, marking an increase of 2.85.
- For Return On Assets (%), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 0.06, marking an increase of 2.77.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 1.5. It has decreased from 1.48 (Mar 24) to 0.01, marking a decrease of 1.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.01, marking a decrease of 1.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 39.00. This value is within the healthy range. It has increased from -486.00 (Mar 24) to 39.00, marking an increase of 525.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.50. This value is within the healthy range. It has increased from -486.00 (Mar 24) to 29.50, marking an increase of 515.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5.99. It has increased from 4.34 (Mar 24) to 5.99, marking an increase of 1.65.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is 767.96. This value exceeds the healthy maximum of 15. It has increased from -29.76 (Mar 24) to 767.96, marking an increase of 797.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 0.81 (Mar 24) to 1.12, marking an increase of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.03 (Mar 24) to 0.00, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amerise Biosciences Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.14% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 29.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.01
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 102 (Industry average Stock P/E: 52.57)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 24, Laxmi Chambers, Ahmedabad Gujarat 380014 | amradeepindustries@gmail.com http://www.amerisebiosciencesltd.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dineshkumar Rathod | WholeTime Director & CFO |
| Ms. Manisha Patel | Director |
| Mr. Kelash Bunkar | Director |
FAQ
What is the intrinsic value of Amerise Biosciences Ltd?
Amerise Biosciences Ltd's intrinsic value (as of 11 December 2025) is 0.13 which is 79.03% lower the current market price of 0.62, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4.10 Cr. market cap, FY2025-2026 high/low of 1.45/0.55, reserves of ₹-1.28 Cr, and liabilities of 8.39 Cr.
What is the Market Cap of Amerise Biosciences Ltd?
The Market Cap of Amerise Biosciences Ltd is 4.10 Cr..
What is the current Stock Price of Amerise Biosciences Ltd as on 11 December 2025?
The current stock price of Amerise Biosciences Ltd as on 11 December 2025 is 0.62.
What is the High / Low of Amerise Biosciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Amerise Biosciences Ltd stocks is 1.45/0.55.
What is the Stock P/E of Amerise Biosciences Ltd?
The Stock P/E of Amerise Biosciences Ltd is 102.
What is the Book Value of Amerise Biosciences Ltd?
The Book Value of Amerise Biosciences Ltd is 0.81.
What is the Dividend Yield of Amerise Biosciences Ltd?
The Dividend Yield of Amerise Biosciences Ltd is 0.00 %.
What is the ROCE of Amerise Biosciences Ltd?
The ROCE of Amerise Biosciences Ltd is 0.19 %.
What is the ROE of Amerise Biosciences Ltd?
The ROE of Amerise Biosciences Ltd is 0.19 %.
What is the Face Value of Amerise Biosciences Ltd?
The Face Value of Amerise Biosciences Ltd is 1.00.